Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Urinary Bladder Neoplasms 1 Recurrence 1 Multiple Myeloma 1 Lung Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 49 Pemetrexed 38 Cisplatin 34 Radiotherapy 32 Docetaxel 31 Gemcitabine 25 Paclitaxel 24 Nivolumab 18 pembrolizumab 15 Etoposide 15 Radiosurgery 13 Erlotinib Hydrochloride 11 Bevacizumab 11 Magnetic Resonance Spectroscopy 10 Vinorelbine 9 Radiation 9 Cyclophosphamide 7 durvalumab 6 Gefitinib 6 Fluorodeoxyglucose F18 6 Celecoxib 6 atezolizumab 5 Oxaliplatin 5 Irinotecan 5 Immunoglobulin G 5 Drug Therapy 5 Disulfides 5 Dexamethasone 5 Chemotherapy, Adjuvant 5 vandetanib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lung Neoplasms × erdafitinib × Clear all

NCT03827850 2023-06-09

FIND

Lung Cancer Group Cologne

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡